We are developing

a new generation of medicines

based on the human microbiome.

We provide new solutions based on the human microbiome for sufferers of serious chronic diseases for which there is currently no other therapy.

ABOUT US

Mikrobiomik

We are a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome and provide new solutions in serious, chronic diseases for which there is currently no other therapy. We aspire to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome and to be the first company in the world to market a medicine based on faecal microbiota in the EU.

Learn more
WE DEVELOP MEDICINES

C. difficile

C. difficile is the main pathogen responsible for acquired diarrhoea in hospitalised patients, which is known as C. difficile infection (CDI) and accounts for 20% of antibiotic-associated diarrhoea and colitis cases. The incidence of CDI has been increasing, both in hospitalised patients and in the community. This is partly due to the appearance of hypervirulent strains, but also to improvements in diagnostic methods and the sometimes non-rational use of antibiotics.

More information

Latest news

27/06/2019 in Corporate

Mikrobiomik reaches final of CEBEK Emprende awards

Mikrobiomik was shortlisted as a finalist for the 2nd CEBEK Emprende awards, sponsored by the Bizkaia Business Confederation. Left to right: Francisco Javier Azpiazu (CEBEK), Juan Basterra CEO of Mikrobiomik…
Read More
09/05/2019 in Corporate

Mikrobiomik moves to BIC Bizkaia

Mikrobiomik moves to new premises at the BIC Bizkaia business incubator. Just a year after its founding, and with the approval of the Governing Board of the Bizkaia Science and…
Read More